The Life Sciences team advised BridgeBio Pharma, Inc. (Nasdaq: BBIO) on its strategic collaboration with Helsinn Group to co–develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors.
BridgeBio is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers.
Helsinn is a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track record of commercial execution.
The joint collaboration for BridgeBio’s GPX4 inhibitor was established as part of a new non-exclusive collaboration framework between BridgeBio and Helsinn that allows the companies to propose co-development and co-commercialization opportunities for preclinical precision oncology programs.
The BridgeBio and Helsinn collaboration builds on the $2.45 billion USD global license and collaboration agreement signed in March 2021 for development of BridgeBio’s FGFR inhibitor infigratinib in oncology indications.
The Goodwin team Noelle Dubiansky, Alexandra Haas, and Joe Thomas (Licensing); Maggie Wong (Corporate); Paul Jin and Ortal Ben Aharon (Antitrust); and Dan Karelitz (Tax).
For more details, read the press release and articles in Fierce Biotech and Endpoints.